Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) Debt to equity
Smith & Nephew SNATS, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.6×, up 0.0× from fiscal 2025 (0.6×). Over the past ten years it has ranged from 0.3× (fiscal 2018) to 0.6× (fiscal 2020); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.6× | (2.93%) |
| FY2024 | 0.6× | 39.21% |
| FY2023 | 0.4× | (13.81%) |
| FY2022 | 0.5× | 0.82% |
| FY2021 | 0.5× | (19.47%) |
| FY2020 | 0.6× | 65.33% |
| FY2019 | 0.4× | 43.95% |
| FY2018 | 0.3× | (12.89%) |
| FY2017 | 0.3× | (22.45%) |
| FY2016 | 0.4× | 9.26% |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.6× | 3.23% |
| Dec 2025 | 0.6× | 0.86% |
| Jun 2025 | 0.6× | (3.75%) |
| Dec 2024 | 0.6× | (1.65%) |
| 18 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| GMED Globus Medical, Inc. compare | 0.0× |
| TXG 10x Genomics compare | 0.0× |
| PEN Penumbra, Inc. compare | 0.0× |
| GKOS Glaukos Corporation compare | 0.1× |
| BIO Bio-Rad Laboratories, Inc. compare | 0.2× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 0.2× |
| PODD Insulet Corporation compare | 0.6× |
| SNN Smith & Nephew SNATS, Inc. | 0.6× |
| BRKR Bruker Corporation compare | 0.7× |
| Medical Devices industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement